Pregabalin for the treatment of painful neuropathy

Expert Review of Neurotherapeutics

Volumn 6, Issue 11, 2006, Pages 1629-1635

  Sonnett, Travis E ^a   Setter, Stephen M ^a   Campbell, R Keith ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Diabetic peripheral neuropathy; Neuropathic pain; Neuropathy; Postherpetic neuralgia; Pregabalin

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; DIAZEPAM; DULOXETINE; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; PARACETAMOL; PLACEBO; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT;

AREA UNDER THE CURVE; BIRTH DEFECT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DEATH; DEPRESSION; DIABETIC NEUROPATHY; DISABILITY; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; HEADACHE; HEART INFARCTION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; LABORATORY TEST; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ANALGESICS; CLINICAL TRIALS; GAMMA-AMINOBUTYRIC ACID; HUMANS; NEURALGIA; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 33845421723     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.11.1629     Document Type: Review

References (34)

1. Ziegler D, Gries FA, Spuler M et al. The epidemiology of diabetic neuropathy. J. Diabetes Complicat. 6(1), 49-57 (1992).
2. Calcutt NA. Potential mechanisms of neuropathic pain in diabetes. Int. Rev. Neurobiol. 50, 205-228 (2002).
3. Bowsher D. The management of postherpetic neuralgia. Postgrad. Med. J. 73(864), 623-629 (1997).
4. Dworkin RH, Schmader KE. Epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: Herpes Zoster and Postherpetic Neuralgia. (2nd Edition). Watson CPN, Gershon AA (Eds). Elsevier Press, NY, USA, 39-64 (2001).
5. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42(2), 229-236 (2002).
6. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J. Pain 5(3), 143-149 (2004).
7. Freynhagen R, Strojek L, Greising T et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trial of flexible and fixed dose regimens. Pain 115(3), 254-263 (2005). • Clinical trials and data relevant to the use of pregabalin in neuropathic conditions.
8. Macdonald RL, Kapur J. Acute cellular alterations in the hippocampus after status epilepticus. Epilepsia 40(Suppl. 1), S9-S20 (1999).
9. Whitworth TL, Quick MW. Upregulation of gamma-aminobutyric acid transporter expression: role of alkylated γ-aminobutyric acid derivatives. Biochem. Soc. Trans. 29(6), 736-741 (2001).
10. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 12(5), 300-306 (2003).
11. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett. 280(2), 107-110 (2000).
12. Lyrica® package insert. Pfizer Inc., New York, NY, USA.
13. Stahl S. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as α(2)δ ligands at voltage-gated calcium channels. J. Clin. Psychiatry 65(8), 596-597 (2004).
14. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105(1-2), 133-141 (2003).
15. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45(Suppl. 6), 13-18 (2004).
16. Huckle R. Pregabalin (Pfizer). Curr. Opin. Investig. Drugs 5(1), 82-89 (2004).
17. Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. Drugs 65(1), 111-118 (2005). • Clinical overview of pregabalin and its place in the treatment of postherpetic neuralgia.
18. Bockbrader HN, Hunt T, Strand JC et al. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two Phase 1 studies. Neurology 54(Suppl. 3), A421 (2000).
19. Randinitis EJ, Posvar EL, Alvey CW et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 43(3), 277-283 (2003). • Important dosing information relevant to the use of pregabalin in the renally impaired patient.
20. Rosenstock J, Tuchman M, LaMoreaux L et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110(3), 624-638 (2004). • Clinical trials and data relevant to the use of pregabalin in neuropathic conditions.
21. Melzak R. The short-form McGill pain questionnaire. Pain 30(2), 191-197 (1987).
22. Lesser H, Sharma U, LaMoreaux L et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63(11), 2104-2110 (2004). • Clinical trials and data relevant to the use of pregabalin in neuropathic conditions.
23. Richter RW, Portenoy R, Sharma U et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain 6(4), 253-260 (2005). • Clinical trials and data relevant to the use of pregabalin in neuropathic conditions.
24. Dworkin RH, Corbin AE, Young JP et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60(8), 1274-1283 (2003). • Clinical trials and data relevant to the use of pregabalin in neuropathic conditions.
25. Sabatowski R, Galvez R, Cherry DA et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized, placebo-controlled clinical trial. Pain 109(1-2), 26-35 (2004). • Clinical trials and data relevant to the use of pregabalin in neuropathic conditions.
26. Van Seventer R, Feister HA, Young JP et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr. Med. Res. Opin. 22(2), 375-384 (2006). • Clinical trials and data relevant to the use of pregabalin in neuropathic conditions.
27. Argoff CE, Backonja MM, Belgrade MJ et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin. Proc. 81(Suppl. 4), S12-S25 (2006). •• Clinical trial interpretation and stratification of data regarding available treatments for diabetic neuropathy and their place in therapy.
28. Argoff CE, Backonja MM, Belgrade MJ et al. Diabetic peripheral neuropathic pain: consensus guidelines for treatment. J. Fam. Pract. 55(6), 1-20 (2006).
29. Gilron I, Bailey JM, Tu D et al. Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 352(13), 1324-1334 (2005).
30. Burgoon CF, Bugoon JS, Baldridge GD. The natural history of herpes zoster. JAMA 164, 265-269 (1957).
31. Weis O, Swiratanakul K, Weintraub M. Treatment of post herpetic neuralgia and acute herpetic pain with amitriptyline and prophenazine. S. Afr. Med. J. 62, 274-275 (1982).
32. Boon R. Efficacy and safety of famciclovir in the treatment of herpes zoster. In: Proceedings of the International Conference on the Varicella Zoster Virus. Paris, France (1995).
33. Li C, Zhang X, Matthews E et al. Calcium channel α2δ1 subunit mediates spinal hyperexcitability in pain modulation. Pain 125(1-2), 20-34 (2006).
34. Li C, Song Y, Higuera E et al. Spinal dorsal horn calcium channel α2δ1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J. Neurosci. 24(39), 8494-8499 (2004).